- Home
- SYNA vs GLPG Comparison
SYNA vs GLPG Comparison
Compare SYNA & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYNA | GLPG |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2002 | 2005 |
Fundamental Metrics
Financial Performance| Metric | SYNA | GLPG |
|---|---|---|
| Price | $77.54 | $31.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $89.13 | $31.33 |
| AVG Volume (30 Days) | ★ 480.5K | 111.0K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,109,100,000.00 | $336,643,201.00 |
| Revenue This Year | $11.70 | $3.61 |
| Revenue Next Year | $11.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.24 | 10.31 |
| 52 Week Low | $41.80 | $22.36 |
| 52 Week High | $89.81 | $37.78 |
Technical Indicators
Market Signals| Indicator | SYNA | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 62.06 | 51.01 |
| Support Level | $66.86 | $31.41 |
| Resistance Level | $81.85 | $32.75 |
| Average True Range (ATR) | 2.50 | 0.51 |
| MACD | 1.26 | 0.16 |
| Stochastic Oscillator | 76.36 | 51.23 |
Price Performance
Historical ComparisonAbout SYNA Synaptics Incorporated $0.001 Par Value
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.